Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07197866 · ClinicalTrials.gov registry record · Phase 2
An Extension Trial to Test if TEV-56286 is Effective in Relieving Multiple System Atrophy
A Phase 2 study of Multiple System Atrophy, sponsored by Teva Branded Pharmaceutical Products R&D.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 200
- Enrollment target
- 5
- Study locations
NCT07197866 is a Phase 2 study of Multiple System Atrophy that is actively recruiting participants, run by Teva Branded Pharmaceutical Products R&D. The registered enrollment target is 200 participants, below the 262-participant average among 30 other Multiple System Atrophy trials with a reported enrollment target (24% lower). The trial reports 5 study locations across 3 states.
The verdict
NCT07197866, a Phase 2 study of Multiple System Atrophy, is actively recruiting participants, sponsored by Teva Branded Pharmaceutical Products R&D.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 200 participants
- Enrollment target
- 5
- Study locations
Study Summary
The primary objective of the trial is to describe the long-term safety and tolerability of TEV-56286 administered orally for the treatment of adult participants with Multiple System Atrophy (MSA). A secondary objective of the trial is to further describe the safety and tolerability of TEV-56286. The planned total duration of the trial is approximately 100 weeks.
Conditions Studied
Interventions
- DRUG TEV-56286
Study Locations (5)
Other
- Teva Investigational Site 32818 - Dresden
- Teva Investigational Site 80203 - Haifa
- Teva Investigational Site 31324 - Barcelona
Florida
- Teva Investigational Site 15544 - Boca Raton
Washington
- Teva Investigational Site 15543 - Spokane
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2025-09-30 |
| Est. Completion | 2029-05-17 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07197866
The ClinicalTrials.gov registry entry for NCT07197866 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 262-participant average among 30 other Multiple System Atrophy trials with a reported enrollment target (24% lower). The listed sponsor is Teva Branded Pharmaceutical Products R&D, which has 167 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Multiple System Atrophy appearing as the primary indexed condition, and to 1 intervention - of which TEV-56286 is the first listed.
NCT07197866 reports 5 study locations spanning 3 distinct geographic areas - top geographies include Other, Florida, Washington.
Frequently Asked Questions
What is clinical trial NCT07197866 about?
NCT07197866 is a clinical study titled "An Extension Trial to Test if TEV-56286 is Effective in Relieving Multiple System Atrophy". The primary objective of the trial is to describe the long-term safety and tolerability of TEV-56286 administered orally for the treatment of adult participants with Multiple System Atrophy (MSA). A secondary objective of the trial is to further describe the safety and tolerability of TEV-56286. T...
What is the current status of trial NCT07197866?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 200 participants. The study started on 2025-09-30. Estimated completion is 2029-05-17.
What conditions does trial NCT07197866 study?
This clinical trial studies the following conditions: Multiple System Atrophy.
What interventions are being tested in trial NCT07197866?
The interventions under investigation include: TEV-56286 (DRUG).
Who is sponsoring clinical trial NCT07197866?
This trial is sponsored by Teva Branded Pharmaceutical Products R&D, which has 167 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07197866 being conducted?
This trial has 5 study locations across Florida, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple System Atrophy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase 2 Study of YA-101 in Patients With Multiple System Atrophy
RECRUITING · Phase 2
-
A Trial to Test if TEV-56286 is Effective for Treatment of Participants With Multiple System Atrophy
RECRUITING · Phase 2
-
A Phase 2a Study of Foralumab Nasal in Patients With Multiple System Atrophy (MSA)
RECRUITING · Phase 2
-
A Study of Lu AF82422 in Participants With Multiple System Atrophy
ACTIVE NOT RECRUITING · Phase 2
-
Randomized Double-Blind Placebo-Controlled Adaptive Design Trial Of Intrathecally Administered Autologous Mesenchymal Stem Cells In Multiple System Atrophy
ACTIVE NOT RECRUITING · Phase 2
-
Effect of Midodrine vs Abdominal Compression on Cardiovascular Risk Markers in Autonomic Failure Patients
RECRUITING · Early Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.